Benefits
Lowers E. coli levels within the gut microbiota
In a placebo-controlled crossover trial in healthy adults, the number of E. coli gene reads in stool fell by about 40% on average after four weeks on the phage blend, versus about 14% on placebo, with a great deal of variation between people. An independent review read this as a real but not substantial phage effect, far short of clearing the bacteria.
Leaves overall gut microbiome diversity unchanged
Across the human trials, the overall richness and diversity of the gut bacterial community did not shift, which the researchers read as selective action rather than the broad disruption antibiotics can cause. A few individual groups changed, such as more butyrate-producing Eubacterium and less Clostridium perfringens, but these were exploratory findings in small groups.
Studied as a probiotic add-on for digestive comfort
In a four-week trial of 68 healthy adults, those taking a B. lactis probiotic together with the phage blend improved on a self-rated gut inflammation symptom score, which the probiotic alone did not. When the three groups were compared after adjusting for starting values the combination did not differ, and there was no phage-only arm to show the phages' own contribution.
Well tolerated over four-week gut-health trials
In the safety crossover trial in adults with mild to moderate digestive complaints, blood chemistry stayed within normal ranges and one liver enzyme fell during the phage period. The authors judged the blend safe and tolerable. Digestive symptoms eased during both the phage and the placebo periods, so that study could not isolate a benefit coming from the phages themselves.
Taken at a low dose as a prebiotic that is not a fiber
The blend is sold as a prebiotic given in milligram amounts, unlike the grams of fermentable fiber usual prebiotics require, and the rationale is that thinning out E. coli frees space for friendlier bacteria. An expert consensus defines a prebiotic as a substrate microbes use for a health benefit, which a virus that kills bacteria fits only loosely.
Mechanism of action
Host-specific infection and bursting of E. coli
A bacteriophage is a virus that latches onto a specific bacterium, injects its genetic material, turns the cell into a factory for new phages and then bursts it. The phages in the studied blend target Escherichia coli. They do not infect human cells and are not live bacteria, so a phage blend is not a probiotic.
Proposed knock-on benefit for other gut bacteria
Researchers suggest that reducing E. coli lowers competition for nutrients and releases cell contents other microbes can use as fuel, which could favor groups such as Bifidobacterium and Lactobacillus. This proposal is the basis of the prebiotic label, and the human trials did not measure it directly.
Needs enough susceptible E. coli to act
Phages multiply only when they meet enough host cells. In the gut trials E. coli made up a small share of stool bacteria and was undetectable in many people, and in a separate oral T4 phage study fecal E. coli counts did not fall. This helps explain why the effects are small and vary so much between people.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial of one 15 mg capsule of a four-strain E. coli bacteriophage blend taken daily for 28 days per arm with a two-week washout. (Gindin et al. 2019, J Am Coll Nutr)
43 healthy adults with self-reported mild to moderate gastrointestinal distress enrolled; 36 completed at least one arm and 32 completed both.
Comprehensive metabolic panel values stayed within clinically acceptable ranges and aspartate aminotransferase fell during the phage period. Participants reported improvements in several digestive symptoms during both the phage and the placebo periods, and questionnaire data showed carryover between periods, so the trial could not show a symptom benefit specific to the phages. The authors concluded the blend was safe and tolerable.
Microbiota and biomarker analysis of the same crossover trial, funded by Deerland through an unrestricted educational grant. (Febvre et al. 2019, Nutrients)
36 normal-weight to overweight adults with self-reported gastrointestinal distress.
Stool E. coli reads fell about 40% on average after the phage period versus about 14% after placebo, with wide variation between people. Overall alpha and beta diversity did not change. Butyrate-producing Eubacterium rose and a Clostridium perfringens group fell. Short-chain fatty acids, inflammatory markers and blood lipids were largely unaltered, while circulating interleukin-4 showed a small but significant decrease.
Four-week randomized, double-blind, placebo-controlled three-arm trial of placebo, B. lactis BL04, or B. lactis BL04 plus the phage blend; the maker supplied the materials and approved the design. (Grubb et al. 2020, Nutrients)
68 healthy adults enrolled, 66 completed.
Only the combination group improved within-group on the gastrointestinal inflammation symptom score (p = 0.01), with a trend for colon pain (p = 0.08); the probiotic alone did not. Comparisons between the three groups after adjusting for baseline showed no differences. Lactobacillus and short-chain fatty acid producers rose more with the combination than with the probiotic alone. There was no phage-only arm.
Cardiovascular analysis of the same four-week program, which also included a separate Bacillus subtilis DE111 arm. (Trotter et al. 2020, Benef Microbes)
Healthy adults aged 18 to 65 with a body mass index of 20 to 34.9.
Measured cardiovascular parameters did not change in people taking B. lactis with or without the phage blend. Only the separate B. subtilis DE111 arm lowered total and non-HDL cholesterol. Nothing here points to a heart-health role for the phage blend.
Dose-ranging safety study of oral E. coli phage T4 given in drinking water, measuring the bioavailability of oral phage in people; it did not test the supplement phage blend. (Bruttin et al. 2005, Antimicrob Agents Chemother)
15 healthy adult volunteers given a lower phage dose, a higher phage dose and placebo.
Fecal phage appeared in a dose-dependent way and cleared within a week of stopping. Oral phage did not lower total fecal E. coli counts, and no substantial phage replication on the volunteers' own E. coli was seen. No phage-related adverse events occurred and liver enzymes stayed normal. Class evidence on oral E. coli phages, not on the supplement blend.
Randomized trial of oral T4-like coliphages or a commercial Russian coliphage product versus placebo over four days, funded by Nestle; it did not test the supplement phage blend. (Sarker et al. 2016, EBioMedicine)
Bangladeshi children hospitalized with acute bacterial diarrhea; an interim analysis after 120 patients.
No adverse events were attributable to the oral phages, which passed safely through the gut but did not amplify there and did not improve diarrhea outcomes over standard care. The authors pointed to insufficient phage coverage and E. coli titers too low for the phages to multiply. Class evidence relevant to any oral E. coli phage product.